What does specialty — gain (loss) from litigation settlement mean?

Represents the net financial impact of legal settlements, including damages paid or received, related to the specialty pharmaceutical segment. This metric reflects non-recurring legal outcomes that can significantly impact segment profitability and risk profile.

Amneal Pharmaceuticals, Inc. AMRX Specialty — Gain (Loss) from Litigation Settlement

Other segment segments

Affordable Medicines

-$1.78M-11,244%

AvKARE

$0—

Similar metrics at other companies

DOWPackaging & Specialty Plastics — Gain (Loss) Related to Litigation Settlement

$26M—

XPO

XPOLitigation settlement gain (loss)

$0-100%

MCKLitigation settlement gain (loss)

$1M—

WDCLitigation settlement gain (loss)

$0-100%

ELLitigation settlement gain (loss)

$0—

SYYLitigation settlement gain (loss)

$122M—

Other financials

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation

See full

Market cap$5.17B+51.0%

Enterprise value$7.55B+33.4%

P/E42.4×—

P/S1.7×+0.5×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity127.9×+119×

Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — gain (loss) from litigation settlement.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s specialty — gain (loss) from litigation settlement?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — gain (loss) from litigation settlement of $0 in Q1 2026.
What does specialty — gain (loss) from litigation settlement mean?: Represents the net financial impact of legal settlements, including damages paid or received, related to the specialty pharmaceutical segment. This metric reflects non-recurring legal outcomes that can significantly impact segment profitability and risk profile.